CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 74 enrolled
Drug / intervention
Vitamin D +1 moredrug
Likely dose
Vitamin D 50000 IUfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01029002
NCT01029002Phase 3Completed
CompareCT.gov

The Effects of Vitamin D Repletion in Vitamin D Deficient Patients With Stage 3 and 4 Chronic Kidney Disease

Albert Einstein College of Medicine·interventional·Posted Dec 9, 2009·Updated Aug 16, 2023

In Brief

A Phase 3 clinical trial evaluating Vitamin D and Placebo for Chronic Renal Insufficiency and Proteinuria. Completed, enrolled 74 participants across 1 site.

Detailed Summary

A randomized clinical trial to determine if vitamin D repletion in CKD (Chronic Kidney Disease) patients with low vitamin D levels will decrease proteinuria, a marker of kidney damage.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Renal Insufficiency, Proteinuria
CountriesUnited States
CollaboratorsNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Timeline

Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 9, 2009
Enrollment StartOct 1, 2009
Primary CompletionJun 1, 2014
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 16.6 years ago

Interventions

Vitamin Ddrug

Vitamin D, ergocalciferol, 50000 IU, weekly for 12 weeks, with open label extension for another 3 months

Placeboother

Patients randomized to this arm will receive one placebo pill once weekly.